Navigation Links
Boehringer Ingelheim Comments on June 18th FDA Advisory Committee Meeting
Date:6/18/2010

RIDGEFIELD, Conn., June 18 /PRNewswire/ -- The Reproductive Health Drugs Advisory Committee met today to discuss the new drug application (NDA) for flibanserin 100 mg as a treatment for Hypoactive Sexual Desire Disorder (HSDD) in pre-menopausal women.  The advisory committee was convened by and makes recommendations to the U.S. Food and Drug Administration (FDA).  The FDA will consider the committee's advice as part of its final assessment of the NDA.  

The committee recognized the significant unmet medical need for women with HSDD and the lack of approved treatments for this condition.  Members of the committee advised that additional data are necessary to further support the efficacy and safety profile of flibanserin and recommended that clinical development of the drug continue.

"We are disappointed with the advisory committee's recommendations and will work with the FDA to address questions raised by the advisory committee," said Christopher Corsico, M.D., M.P.H., U.S. medical director, Boehringer Ingelheim Pharmaceuticals, Inc.  "Our ongoing flibanserin clinical trial program demonstrates our continued commitment to women with HSDD."


'/>"/>
SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Boehringer Ingelheim Receives Top Honor as Worlds Most Respected Biopharmaceutical Employer in Science 2007 Top Employers Survey
2. Dalton Medicinal Chemistry Partners Achieves Milestone in Collaboration with Boehringer Ingelheim (Canada) Ltd.
3. Astellas and Boehringer Ingelheim Reach Settlement Agreement with Ranbaxy on Flomax Patent Case
4. Dalton Medicinal Chemistry Partners Achieves Another Milestone in Collaboration with Boehringer Ingelheim (Canada) Ltd.
5. Boehringer Ingelheim Pharmaceuticals, Inc. Receives the NCQA Seal Of Approval
6. More Than Half of Patients Treated for Benign Prostatic Hyperplasia Receive Boehringer Ingelheims Flomax as First-Line Therapy
7. Boehringer Ingelheim and BioSpace Search for Scientists at Career Fair in Boston, Massachusetts
8. Rentschler Biotechnologie Announces Cooperation with Boehringer Ingelheim
9. Ingenuity Systems Announces Multi-Year Agreement With Boehringer Ingelheim
10. Boehringer Ingelheim and Micromet Announce Global Collaboration for Multiple Myeloma BiTE Antibody
11. Former Banc of America Securities Analyst David Maris Comments on Decision by Biovail to Drop Its Claims Against Him; Denies That He is Cooperating With Biovail
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... Ellen Matloff, president and ... Council (CTC) as a 2017 Women of Innovation® finalist. Matloff will be among ... Dinner. , The dinner recognizes women accomplished in science, technology, engineering and math ...
(Date:3/23/2017)... , March 23, 2017  Agriculture technology company ... A financing and note conversion to commercialize its Cool ... is focused on developing products that are simultaneously profitable ... million in the last 18 months. This latest round ... Bridge Venture Partners. The company,s primary ...
(Date:3/22/2017)... ... March 22, 2017 , ... ... regeneration from small lab samples to full-size tissues, bones, even whole organs to ... vascular system that delivers blood deep into the developing tissue. , Current ...
(Date:3/22/2017)... JERUSALEM , March 22, 2017 ... ( www.oramed.com ), ... of oral drug delivery systems, announced today that ... Officer, will deliver a presentation titled, "Oral Insulin ... upcoming Cambridge Healthtech Institute,s Oligonucleotide and Peptide Therapeutics ...
Breaking Biology Technology:
(Date:3/2/2017)... March 2, 2017 Australian stem cell and ... CYP), has signed an agreement with the Monash Lung ... Biomedicine Discovery Institute and Department of Pharmacology at Monash ... further preclinical study to support the use of Cymerus™ ... Asthma is a chronic, long term ...
(Date:2/27/2017)... , Feb. 27, 2017   Strategic Cyber Ventures ... it has led a $3.5 million investment in  Polarity ... Strategic Cyber Ventures is DC based and is led ... Hank Thomas . Ron Gula , also a ... also participated in this series A round of funding. ...
(Date:2/21/2017)... -- Der weltweite Biobanking-Sektor wird bis zum ... mit mehr als 50 Vertretern aus verschiedenen Branchen wurde aber ... diese Prognose zu realisieren. ... Zu den Schwierigkeiten für ... für die Biobank, die Implementierung Zeit sparender Technologien, ein ...
Breaking Biology News(10 mins):